Showing results (1611-1620 of 2,100) with videos related to
Sort By:
Pageof 210
Journal of Immunology (Baltimore, Md. : 1950)|April 1, 1986
Recombinant human interleukin 1 alpha: purification and biological characterizationU Gubler, A O Chua, A S Stern, et al.Journal of Hematology & Oncology|March 13, 2022
Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patientsChristina Zeller, Daniel Richter, Vindi Jurinovic, et al.Brain and Behavior|June 28, 2024
The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRIEsther Ganelin-Cohen, Chen Buxbaum, Noam Bosak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.Inflammatory Bowel Diseases|November 15, 2019
Microbial Shifts and Shorter Time to Bowel Resection Surgery Associated with C. difficile in Pediatric Crohn's DiseaseJennifer Hellmann, Heidi Andersen, Lin Fei, et al.BMC Infectious Diseases|March 29, 2022
Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workersIrit Nachtigall, Marzia Bonsignore, Sven Hohenstein, et al.Academic Medicine : Journal of the Association of American Medical Colleges|June 30, 2016
Entrusting Observable Practice Activities and Milestones Over the 36 Months of an Internal Medicine ResidencyEric J Warm, Justin D Held, Michael Hellmann, et al.Leukemia & Lymphoma|June 6, 2013
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory diseaseJacob D Soumerai, Matthew D Hellmann, Yang Feng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLCLaurent Dercle, Matthew Fronheiser, Naiyer A Rizvi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2019
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibA J Schoenfeld, K C Arbour, H Rizvi, et al.Pageof 210